Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for early stage cancer research

Alacris Theranostics GmbH / Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for early stage cancer research . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Berlin, 14th November 2012  -  Alacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris' proprietary ModCell(TM) System, developed at the Max Planck Institute for ...

Berlin, 14th November 2012  -  Alacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris' proprietary ModCell^TM System, developed at the Max Planck Institute for Molecular Genetics and licensed exclusively to Alacris, for drug stratification using data from early stage cancer drug discovery at GSK.

GSK will provide to Alacris pre-clinical biology data from a drug discovery project in oncology. Alacris will exploit its proprietary Systems Biology model to determine the in silico effect of the inhibitor in its "virtual clinical trial" system. Alacris will then suggest which cancer cell lines as well as which cancers are more likely to respond to the inhibitor. This will be based on whole genome and transcriptome data that is integrated in the Alacris' cancer model ModCell^TM

About Alacris Theranostics GmbH:

Alacris Theranostics (www.alacris.de) is a company based in Berlin specialized in developing new approaches in personalized medicine for cancer patient diagnosis, treatment and drug stratification. Alacris Theranostics is applying a systems biology approach exclusively licensed as ModCell^TM to Alacris. Based on genome and transcriptome information obtained by next generation sequencing and including kinetic pathway information, mutation and drug databases, the systems biology approach is providing a "Virtual Patient" model. The "Virtual Patient" model can predict the effect of drug treatment and optimized combinatory treatment providing means for cancer patient stratification and for personalized medicine approaches. In addition Alacris' "Virtual Clinical Trials" system permits the in silico analysis of drugs, thus identifying specific patient groups or particular genetic profiles and diseases that could be targeted by the drug, with the goal of more efficient and precise treatment of patients.  

Contact:

Alacris Theranostics GmbH
Dr Bodo Lange, CEO

Fabeckstrasse 60-62
D-14195 Berlin
Germany
Phone: +49 30 841 312 01
Email: [email protected]

www.alacris.de

MC Services AG
Anne Hennecke, Managing Partner
Phone +49 89 210 228 18
Email: [email protected]
Copyright Thomson Reuters

Attachment(s)
http://hugin.info/155582/R/1657734/536257.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE


[HUG#1657734]